SOURCE: MMR Information Systems, Inc.

MMR Information Systems, Inc.

June 22, 2009 08:44 ET

MMR Information Systems Pursues International Patent Applications on Anti-CD20 Antibodies

Drug Is Potential Candidate as Next Generation Rituximab

LOS ANGELES, CA--(Marketwire - June 22, 2009) - MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that it has taken the necessary steps to file for extensions of the Company's Patent Cooperation Treaty (PCT) patent application on anti-CD20 monoclonal antibodies to the national phase through filings in major European, Asian, North American, and South American markets.

Anti-CD20 antibodies are useful in treating B-Cell malignancies, including Non-Hodgkin Lymphoma (NHL) and additional B-Cell mediated conditions such as rheumatoid arthritis. The Company's anti-CD20 antibody asset is potentially a candidate for the next generation Rituximab. Rituximab, currently marketed under the trade name Rituxan® in the United States by Biogen Idec and Genentech (wholly owned member of the Roche Group) and under the name MabThera® by Roche in the rest of the world except Japan, where it is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd., is one of the world's most successful monoclonal antibodies with reported total sales in 2008 in excess of USD $5.4 billion.

MMR Information Systems, Inc. acquired the technology through its reverse merger with Favrille, Inc., which was completed in January 2009. Favrille had previously acquired the technology from Diversa Corporation (now Verenium Corporation). According to consultants to the Company and former science executives of Favrille, Inc., and based on Diversa's pre-clinical research and testing of the scientific evidence, the next generation of Rituximab and further applications of the anti-CD20 antibodies may make the treatment of B-Cell malignancies even more effective in the future.

This second generation technology includes a series of optimized anti-CD20 monoclonal antibodies and provides potential future treatment options for various autoimmune and B-Cell mediated diseases, including lupus nephritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, respiratory distress syndrome, chronic lymphocytic leukemia, multiple sclerosis and vaculitis.

Because of its interest in maximizing shareholder value, MMR Information Systems is working with independent consultants to attempt to monetize these anti-CD20 antibody assets around the world, and will attend meetings at the Drug Information Association's (DIA) Annual Meeting being held in San Diego this week. However, the Company's focus will continue to be on its primary products, the MyMedicalRecords Personal Health Record, MyMedicalRecords Pro for physicians and healthcare professionals, and MyEsafeDepositBox electronic safe deposit box storage solutions.

About MMR Information Systems, Inc.

MMR Information Systems, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, unions and professional organizations. MyMedicalRecords enables individuals and their families to have greater control over their health and well-being by facilitating access to their medical records and other important documents -- such as birth certificates, passports, insurance policies and wills -- anytime from anywhere using the Internet.

The MyMedicalRecords PHR service, accessed through www.mymedicalrecords.com, allows documents, images and voicemail messages to be transmitted and stored in the MyMedicalRecords PHR system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform.

The proprietary MyEsafeDepositBox service, available at www.myesafedepositbox.com, provides secure online storage for vital financial, legal and insurance documents in addition to medical records, and serves as a powerful emergency-preparedness tool for industry, individuals and municipalities.

Information about the MyMedicalRecords Pro service, designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records, is available at www.mymedicalrecordsmd.com.

To learn more about MMR Information Systems, Inc. and its products, visit www.mmrinformationsystems.com. Information on MMR's Web sites is not incorporated by reference into this press release.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements regarding the Company's anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the development and approval of biotechnology product candidates and additional risks discussed in the Company's filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company's behalf) are qualified by the cautionary statements in this notice. MMR Information Systems, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information